Board of Directors

Carol A. Nacy, Ph.D.

Dr. Nacy has been in executive management positions in the biotechnology industry for more than 13 years, following a nearly 20 year academic science career. She was Executive Vice President and Chief Scientific Officer at EntreMed, Inc., from 1993 through its successful public offering in June 1996. She left EntreMed in November 1996 and was Chief Scientific Officer for Anergen, Inc., a California company focused on autoimmune diseases, until the company was acquired by Corixa Corporation in December 1998. Dr. Nacy became full time CEO and Chair of the Board of Sequella, Inc. in January 1999. She is a member of the Board of Directors of several for-profit companies and non-profit agencies. Prior to her business experience, she was a career scientist (GS-15) and Science Manager at the Walter Reed Army Institute of Research, Washington, DC (1976-1993). She continues to serve the scientific research community on grant review committees, scientific advisory boards, and as an officer in scientific societies (President, Society for Leukocyte Biology and American Society for Microbiology)  Dr. Nacy obtained her A.B., M.A., and Ph.D. in Biology (Microbiology and Immunology) from the Catholic University of America, Washington, DC, and is a Fellow of the American Academy of Microbiology.

Leo Einck, Ph.D.

Founder and Chief Scientific Officer
Dr. Einck has worked in the pharmaceutical industry since 1985, and has started and managed several biotechnology companies since his shift to product development. He was the first employee of and later became the Chief Operating Officer of HEM, a company specializing in double-stranded RNA therapeutics for cancer. He managed all aspects of HEM's business, including manufacturing, clinical trials, regulatory affairs, and daily operations. He joined EntreMed, Inc. in 1993 as Director of Sponsored Research, became Vice-President for Extramural Programs in 1996, and then the Vice President for Research Operations. He has over 15 years of experience in start-up companies, in development of products in the biotechnology industry, and has additional education and experience in patent law. He joined Sequella as President in February 1998. Prior to his business experience, Dr. Einck was a molecular biologist at the National Cancer Institute of the NIH for several years following his Ph.D.

Ronald Meltzer, Ph.D., J.D.

Director
Dr. Ronald I. Meltzer is a partner at Wilmer Cutler Pickering Hale and Dorr LLP in Washington, DC.  His practice covers numerous areas of international trade law, including export compliance matters, trade remedy litigation and the regulation of international transactions.  He has also advised U.S. and foreign clients on international joint ventures and technical service agreements.  Prior to joining WilmerHale, Dr. Meltzer was a professor at SUNY/Buffalo, where he specialized in North-South trade relations and multilateral economic institutions.  He has published widely on these topics and speaks frequently at professional conferences.

Bradley Rotter

Director
Mr. Rotter has been a public and private venture investor in telecommunications, aeronautics, and biotechnology for 25 years and has experience as Chairman of a publicly traded Venture Firm. He currently serves on the Board of AirPatrol Corporation. He was the President and then Chief Executive Officer of MR3 Systems, Inc a  Metals Technology Company that was one of Mr. Rotter’s portfolio companies. The San Francisco based company is a publicly traded company that has developed a revolutionary technology for the extraction of metals. He is a graduate of West Point and is active in local politics in California. 

William Hoskins

Director
Mr. Hoskins has a wealth of experience in corporate partnering of new technologies with pharmaceutical companies. Mr. Hoskins was Vice President, Secretary, and General Counsel for the North American operations of Marion, Marion Merrill Dow, and Hoeschst Marion Roussel (now Aventis), where he helped create corporate partnerships of his organizations with a variety of small and large pharmaceutical companies and organized the acquisition of equity interests in a number of companies. He is and has been on the Board of a number of companies and is a Director of the American Arbitration Association. Mr. Hopkins is currently a partner in Resolution Counsel, LLP, a very successful Boston, MA, organization he co-founded to assist in the resolution of disputes between corporate entities.

Lawrence Miller

Secretary
Mr. Miller serves as secretary of the Board of Directors of the Company, but is a nonvoting member. He is also the Corporate Attorney for the Company and has been instrumental in its organization and development of its structure. Mr. Miller has been a Partner in the law firm Grossberg, Yochelson, Fox, & Beyda, in Washington D.C., for thirty years. A significant portion of his practice has been devoted to corporate law as it relates to healthcare organizations.